REV1 and osteosarcoma: In osteosarcoma U2OS cells, the small molecule compound MLAF50 directly interacts with Rev1 UBM2, weakening the interaction between Rev1 UBM2 and ubiquitin and preventing the chromatin localization of Rev1 induced by cisplatin in U2OS cells [137], suggesting that Rev1 UBM2 may serve as a target for small molecule inhibitors for the treatment of osteosarcoma.